Welcome to our dedicated page for 4D Molecular Therapeutics news (Ticker: FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics stock.
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) is a clinical-stage gene therapy company dedicated to developing transformative medicines for serious, unmet medical conditions. Utilizing its proprietary Therapeutic Vector Evolution platform, the company designs novel adeno-associated virus (AAV) vectors to treat genetic diseases.
Core Business: 4DMT focuses on three primary therapeutic areas: Ophthalmology, Cardiology, and Pulmonology. In ophthalmology, intravitreal vectors are employed for treatments like 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Cardiology projects include 4D-310 for Fabry disease cardiomyopathy, while pulmonology efforts are highlighted by 4D-710 for cystic fibrosis.
Recent Achievements: The company has shown promising interim safety and efficacy data for 4D-310 in treating Fabry disease cardiomyopathy, with significant improvements in cardiac function, exercise capacity, and quality of life. For 4D-150, positive interim results from the PRISM clinical trial indicate its potential as a best-in-class treatment for wet AMD, leading to the initiation of a Phase 3 clinical trial in 2025.
Partnerships and Financial Condition: 4DMT has established strategic partnerships and recently secured substantial financing, bolstering its financial health. The company reported $589 million in cash equivalents by Q1 2024, sufficient to fund operations into the first half of 2027.
Innovative Pipeline: 4DMT’s product candidates, currently in clinical and preclinical stages, include 4D-175 for geographic atrophy, 4D-725 for A1AT deficiency, and additional CNS programs through gene editing partnerships. The company’s advanced manufacturing processes support the potential commercialization of these therapies.
Learn more at www.4DMT.com and follow on LinkedIn.
4D Molecular Therapeutics (FDMT) announced its third quarter 2022 financial results, reporting total revenue of $0.5 million, down from $1.4 million in Q3 2021. The net loss increased to $25.7 million from $22.2 million year-over-year. The company highlighted promising interim data from its Phase 1/2 clinical trial of 4D-710 for cystic fibrosis, showing safety and transgene expression in patients. With $239 million in cash and equivalents, FDMT expects to fund operations into the first half of 2025, emphasizing efficient cash utilization.
4D Molecular Therapeutics (Nasdaq: FDMT) announced positive interim results from the Phase 1/2 trial of 4D-710 for cystic fibrosis at the NACFC. All three patients in Cohort 1 exhibited 100% successful delivery and expression of the CFTR∆R transgene in lung tissue samples. The treatment was well tolerated with no drug-related adverse events reported. Ongoing enrollment for Cohort 2 is underway, and further data is expected in 2023, highlighting the potential of 4D-710 for patients not eligible for current CFTR modulators.
4D Molecular Therapeutics (Nasdaq: FDMT) will present interim clinical data from its Phase 1/2 trial of 4D-710 at the North American Cystic Fibrosis Conference (NACFC) from November 3-5, 2022. The presentation will cover safety, tolerability, delivery, and CFTR transgene expression in cystic fibrosis patients. Following the presentation, a conference call will be hosted on November 3rd at 4:30 PM ET to discuss results. 4D-710 aims to treat cystic fibrosis via aerosol delivery, potentially benefiting a wide range of patients with various CFTR mutations.
4D Molecular Therapeutics (Nasdaq: FDMT) has appointed Noriyuki Kasahara, MD, PhD to its Board of Directors and promoted Fred Kamal, PhD to President and COO. These leadership changes aim to enhance the company's clinical development of five product candidates targeting ophthalmology, cardiology, and pulmonology. Dr. Kasahara brings over 30 years of expertise in gene therapy, while Dr. Kamal's expanded role reflects a commitment to the company's growth. The five clinical candidates are 4D-150, 4D-310, 4D-710, 4D-125, and 4D-110, although none have FDA approval yet.
4D Molecular Therapeutics (Nasdaq: FDMT) announced its participation in two upcoming investor conferences. The first is the Jefferies Cell and Genetic Medicine Summit, featuring a corporate presentation on September 30, 2022, at 9:00 a.m. ET. The second event is Chardan’s 6th Annual Genetic Medicines Conference, where one-on-one meetings will take place on October 3, 2022. A live audio webcast of the presentation will be accessible on the company's website, with a replay available for two weeks post-event. 4DMT specializes in targeted genetic medicines and is advancing five clinical-stage products in various therapeutic areas.
4D Molecular Therapeutics (Nasdaq: FDMT) reported its second quarter 2022 financial results, showing total revenue of $0.2 million, down from $14.6 million in Q2 2021. The company maintained $261.6 million in cash and equivalents, sufficient to fund operations into the first half of 2025. Key developments include the expansion of the eligible patient population for 4D-310's Phase 1/2 trial for Fabry disease to include females. The net loss for the quarter was $28.1 million, compared to $7.6 million in the prior year.
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) has announced its participation in two major investor conferences. The company will present at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 8:00 a.m. ET, followed by a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 8:40 a.m. PT. Investors can access a live audio webcast of these presentations on their website, with replays available for two weeks.
4DMT is focused on targeted genetic medicines using its Therapeutic Vector Evolution platform.
4D Molecular Therapeutics (NASDAQ: FDMT) reported its first quarter 2022 financial results, highlighting key clinical advancements in its pipeline. The firm initiated the treatment of the first patient with 4D-150 for wet AMD and dosed the first patient in a Phase 1/2 trial for 4D-710 targeting cystic fibrosis. Despite these developments, total revenue decreased to $1.2 million from $2.0 million year-over-year. R&D expenses rose to $19.4 million, contributing to a net loss of $26.3 million. The company maintains a strong cash position of $284.5 million, expected to fund operations into 2024.
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) will participate in the 2022 Bank of America Healthcare Conference on May 10, 2022, at 8:40 a.m. PT. The event will feature a fireside chat, accessible via a live audio webcast on the 4DMT website. This clinical-stage biotherapeutics company focuses on genetic medicines and has developed targeted vectors for five clinical products addressing diseases in ophthalmology, cardiology, and pulmonology, including Fabry disease and cystic fibrosis.
4D Molecular Therapeutics (Nasdaq: FDMT) has initiated its Phase 1/2 clinical trial for 4D-710, focusing on treating cystic fibrosis. The first patient has been dosed, marking a significant milestone for the company. This therapy aims to deliver CFTR expression to lung cells, potentially benefiting a wide range of cystic fibrosis patients, especially those unable to use existing treatments. The trial will assess safety, tolerability, and clinical activity, with around 18 patients expected to participate.
FAQ
What is the current stock price of 4D Molecular Therapeutics (FDMT)?
What is the market cap of 4D Molecular Therapeutics (FDMT)?
What is 4D Molecular Therapeutics' core business?
What recent achievements has 4D Molecular Therapeutics accomplished?
What are the key products in 4DMT's pipeline?
How is 4DMT financially positioned?
What partnerships has 4DMT established?
What is the Therapeutic Vector Evolution platform?
What is 4D-150 and what does it treat?
Where can I find more information about 4D Molecular Therapeutics?
What are the clinical-stage products in 4DMT’s pipeline?
What is the significance of 4D-310's interim data for Fabry disease?
